|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2020. CA Cancer J Clin. 70:7–30. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sui H, Ma N, Wang Y, Li H, Liu X, Su Y and
Yang J: Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer:
Toward personalized medicine and combination strategies. J Immunol
Res. 2018:69849482018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
España S, Guasch I and Carcereny E:
Immunotherapy rechallenge in patients with non-small-cell lung
cancer. Pulmonology. 26:252–254. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Duan J, Cui L, Zhao X, Bai H, Cai S, Wang
G, Zhao Z, Zhao J, Chen S, Song J, et al: Use of immunotherapy with
programmed cell death 1 vs programmed cell death ligand 1
inhibitors in patients with cancer: A systematic review and
meta-analysis. JAMA Oncol. 6:375–384. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Califano R, Gomes F, Ackermann CJ, Rafee
S, Tsakonas G and Ekman S: Immune checkpoint blockade for non-small
cell lung cancer: What is the role in the special populations? Eur
J Cancer. 125:1–11. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen Y, Zhou Y, Tang L, Peng X, Jiang H,
Wang G and Zhuang W: Immune-checkpoint inhibitors as the first line
treatment of advanced non-small cell lung cancer: A meta-analysis
of randomized controlled trials. J Cancer. 10:6261–6268. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prelaj A, Tay R, Ferrara R, Chaput N,
Besse B and Califano R: Predictive biomarkers of response for
immune checkpoint inhibitors in non-small-cell lung cancer. Eur J
Cancer. 106:144–159. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choucair K, Morand S, Stanbery L, Edelman
G, Dworkin L and Nemunaitis J: TMB: A promising immune-response
biomarker, and potential spearhead in advancing targeted therapy
trials. Cancer Gene Ther. 27:841–853. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rossi G, Russo A, Tagliamento M, Tuzi A,
Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, et al:
Precision medicine for NSCLC in the era of immunotherapy: New
biomarkers to select the most suitable treatment or the most
suitable patient. Cancers (Basel). 12:11252020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hashemi S, Fransen MF, Niemeijer A, Ben
Taleb N, Houda I, Veltman J, Becker-Commissaris A, Daniels H,
Crombag L, Radonic T, et al: Surprising impact of stromal TIL's on
immunotherapy efficacy in a real-world lung cancer study. Lung
Cancer. 153:81–89. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ying HQ, Liao YC, Luo YR, Xiong G, Huang
Y, Nie RW, Xiong CF and Cheng XX: Cancer-elicited inflammation
attenuates response and outcome in tyrosine kinase inhibitor naive
patients with advanced NSCLC. Pharmacol Res. 170:1057342021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yucel S and Bilgin B: The prognostic
values of systemic immune-inflammation index and derived
neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell
lung cancer. J Oncol Pharm Pract. 27:71–77. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Abdelhamed S, Ogura K, Yokoyama S, Saiki I
and Hayakawa Y: AKT-STAT3 pathway as a downstream target of EGFR
signaling to regulate PD-L1 expression on NSCLC cells. J Cancer.
7:1579–1586. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nagasaka M, Sexton R, Alhasan R, Rahman S,
Azmi AS and Sukari A: Gut microbiome and response to checkpoint
inhibitors in non-small cell lung cancer-a review. Crit Rev Oncol
Hematol. 145:1028412020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim K, Kwon O, Ryu TY, Jung CR, Kim J, Min
JK, Kim DS, Son MY and Cho HS: Propionate of a microbiota
metabolite induces cell apoptosis and cell cycle arrest in lung
cancer. Mol Med Rep. 20:1569–1574. 2019.PubMed/NCBI
|
|
18
|
Mountzios G, Samantas E, Senghas K, Zervas
E, Krisam J, Samitas K, Bozorgmehr F, Kuon J, Agelaki S, Baka S, et
al: P75.04 advanced lung cancer inflammation index (ALI),
neutrophil-to-lymphocyte ratio (NLR), and PD-(L)1 inhibitor
efficacy in NSCLC. J Thorac Oncol. 16 (Suppl):S573–S574. 2021.
View Article : Google Scholar
|
|
19
|
Zhuang H, Cheng L, Wang Y, Zhang YK, Zhao
MF, Liang GD, Zhang MC, Li YG, Zhao JB, Gao YN, et al: Dysbiosis of
the gut microbiome in lung cancer. Front Cell Infect Microbiol.
9:1122019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Capone M, Giannarelli D, Mallardo D,
Madonna G, Festino L, Grimaldi AM, Vanella V, Simeone E, Paone M,
Palmieri G, et al: Baseline neutrophil-to-lymphocyte ratio (NLR)
and derived NLR could predict overall survival in patients with
advanced melanoma treated with nivolumab. J Immunother Cancer.
6:742018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ettinger DS, Wood DE, Aisner DL, Akerley
W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico
AT, et al: NCCN Guidelines Insights: Non-Small Cell Lung Cancer,
Version 2.2021. J Natl Compr Canc Netw. 19:254–266. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Neeman E, Gresham G, Ovasapians N,
Hendifar A, Tuli R, Figlin R and Shinde A: Comparing physician and
nurse eastern cooperative oncology group performance status
(ECOG-PS) ratings as predictors of clinical outcomes in patients
with cancer. Oncologist. 24:e1460–e1466. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hodi FS, Ballinger M, Lyons B, Soria JC,
Nishino M, Tabernero J, Powles T, Smith D, Hoos A, McKenna C, et
al: Immune-modified response evaluation criteria in solid tumors
(imRECIST): Refining guidelines to assess the clinical benefit of
cancer immunotherapy. J Clin Oncol. 36:850–858. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
National Cancer Institute, National
Institutes of Health, U.S. Department of Health and Human Services,
. Common Terminology Criteria for Adverse Events (CTCAE) Version
4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdfDecember
30–2010
|
|
25
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leonetti A, Wever B, Mazzaschi G, Assaraf
YG, Rolfo C, Quaini F, Tiseo M and Giovannetti E: Molecular basis
and rationale for combining immune checkpoint inhibitors with
chemotherapy in non-small cell lung cancer. Drug Resist Updat.
46:1006442019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shiraishi Y, Kishimoto J, Tanaka K,
Sugawara S, Daga H, Hirano K, Azuma K, Hataji O, Hayashi H,
Tachihara M, et al: Treatment rationale and design for APPLE
(WJOG11218L): A multicenter, open-label, randomized phase 3 study
of atezolizumab and platinum/pemetrexed with or without bevacizumab
for patients with advanced nonsquamous non-small-cell lung cancer.
Clin Lung Cancer. 21:472–476. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Low JL, Walsh RJ, Ang Y, Chan G and Soo
RA: The evolving immuno-oncology landscape in advanced lung cancer:
First-line treatment of non-small cell lung cancer. Ther Adv Med
Oncol. 11:17588359198703602019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Watanabe K, Noma D, Masuda H and Masuda M:
Preoperative inflammation-based scores predict early recurrence
after lung cancer resection. J Thorac Dis. 13:2812–2823. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Asher V, Lee J, Innamaa A and Bali A:
Preoperative platelet lymphocyte ratio as an independent prognostic
marker in ovarian cancer. Clin Transl Oncol. 13:499–503. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qu Z, Wang Q, Wang H, Jiao Y, Li M, Wei W,
Lei Y, Zhao Z, Zhang T, Zhang Y and Gu K: The effect of
inflammatory markers on the survival of advanced gastric cancer
patients who underwent anti-programmed death 1 therapy. Front
Oncol. 12:7831972022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song X, Chen D, Yuan M, Wang H and Wang Z:
Total lymphocyte count, neutrophil-lymphocyte ratio, and
platelet-lymphocyte ratio as prognostic factors in advanced
non-small cell lung cancer with chemoradiotherapy. Cancer Manag
Res. 10:6677–6683. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Raungkaewmanee S, Tangjitgamol S,
Manusirivithaya S, Srijaipracharoen S and Thavaramara T:
Platelet-to-lymphocyte ratio as a prognostic factor for epithelial
ovarian cancer. J Gynecol Oncol. 23:265–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao Z, Zhao X, Lu J, Xue J, Liu P and Mao
H: Prognostic roles of neutrophil to lymphocyte ratio and platelet
to lymphocyte ratio in ovarian cancer: A meta-analysis of
retrospective studies. Arch Gynecol Obstet. 297:849–857. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yun NK, Rouhani SJ, Bestvina CM, Ritz EM,
Gilmore BA, Tarhoni I, Borgia JA, Batus M, Bonomi PD and Fidler MJ:
Neutrophil-to-lymphocyte ratio is a predictive biomarker in
patients with epidermal growth factor receptor (EGFR) mutated
advanced non-small cell lung cancer (NSCLC) treated with tyrosine
kinase inhibitor (TKI) therapy. Cancers (Basel). 13:1426–1441.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cao W, Yao X, Cen D, Zhi Y, Zhu N and Xu
L: Prognostic role of pretreatment thrombocytosis on survival in
patients with cervical cancer: A systematic review and
meta-analysis. World J Surg Oncol. 17:1322019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu N, Mao J, Tao P, Chi H, Jia W and Dong
C: The relationship between NLR/PLR/LMR levels and survival
prognosis in patients with non-small cell lung carcinoma treated
with immune checkpoint inhibitors. Medicine (Baltimore).
101:e286172022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qiang H, Chang Q, Xu J, Qian J, Zhang Y,
Lei Y, Han B and Chu T: New advances in antiangiogenic combination
therapeutic strategies for advanced non-small cell lung cancer. J
Cancer Res Clin Oncol. 146:631–645. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
John T, Sakai H, Ikeda S, Cheng Y,
Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, et al:
1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) +
chemotherapy (chemo) in Asian patients (pts) with advanced
non-small cell lung cancer (NSCLC) from CheckMate 9LA. Ann Oncol.
31 (Suppl 4):S847–S848. 2020. View Article : Google Scholar
|
|
40
|
Zhao L, Li Y, Jiang N, Song X, Xu J, Zhu
X, Chen C, Kong C, Wang X, Zong D, et al: Association of blood
biochemical indexes and antibiotic exposure with severe
immune-related adverse events in patients with advanced cancers
receiving PD-1 inhibitors. J Immunother. 45:210–216. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sridhar S, Paz-Ares L, Liu H, Shen K,
Morehouse C, Rizvi N, Segal NH, Jin X, Zheng Y, Narwal R, et al:
Prognostic significance of liver metastasis in Durvalumab-treated
lung cancer patients. Clin Lung Cancer. 20:e601–e608. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carroll HK, Duffy AG and O'Farrelly C:
Liver immunology, immunotherapy, and liver cancers: Time for a
rethink? Semin Liver Dis. Mar 9–2022.(Epub ahead of print).
PubMed/NCBI
|
|
43
|
Chiu DK, Xu IM, Lai RK, Tse AP, Wei LL,
Koh HY, Li LL, Lee D, Lo RC, Wong CM, et al: Hypoxia induces
myeloid-derived suppressor cell recruitment to hepatocellular
carcinoma through chemokine (C-C motif) ligand 26. Hepatology.
64:797–813. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Reck M, Mok TSK, Nishio M, Jotte RM,
Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu
D, Moro-Sibilot D, et al: Atezolizumab plus bevacizumab and
chemotherapy in non-small-cell lung cancer (IMpower150): Key
subgroup analyses of patients with EGFR mutations or baseline liver
metastases in a randomised, open-label phase 3 trial. Lancet Respir
Med. 7:387–401. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Deng M, Ma X, Liang X, Zhu C and Wang M:
Are pretreatment neutrophil-lymphocyte ratio and
platelet-lymphocyte ratio useful in predicting the outcomes of
patients with small-cell lung cancer? Oncotarget. 8:37200–37207.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu N, Jiang A, Zheng X, Fu X, Zheng H,
Gao H, Wang J, Liang X, Tian T, Ruan Z and Yao Y: Prognostic
nutritional index identifies risk of early progression and survival
outcomes in advanced non-small cell lung cancer patients treated
with PD-1 inhibitors. J Cancer. 12:2960–2967. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xia J, Chen Y, Wen S, Du X and Shen B:
Peripheral blood inflammation indicators as predictive indicators
in
immunotherapy of advanced non-small cell lung cancer. Zhongguo
Fei Ai Za Zhi. 24:632–645. 2021.(In Chinese). PubMed/NCBI
|
|
48
|
Balachandran VP, Gonen M, Smith JJ and
DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet
Oncol. 16:e173–e180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng J, Li Y, Wei B, Guo L, Li W, Xia Q,
Zhao C, Zheng J, Zhao J, Sun R, et al: Clinicopathologic
characteristics and diagnostic methods of RET rearrangement in
Chinese non-small cell lung cancer patients. Transl Lung Cancer
Res. 11:617–631. 2022. View Article : Google Scholar : PubMed/NCBI
|
